Skip to main content
Top
Published in: Journal of Cancer Research and Clinical Oncology 11/2017

01-11-2017 | Original Article – Cancer Research

Disseminated tumor cells are not associated with established risk factors, L1CAM immunoreactivity and outcome in endometrial carcinoma

Authors: Stefan Kommoss, Andreas D. Hartkopf, Bernhard Krämer, Anne-Kathrin Bunz, Friederike Grevenkamp, Felix Kommoss, Jana Pasternak, Sabine M. Arbabi, Markus Wallwiener, Annette Staebler, Sigurd F. Lax, Sara Y. Brucker, Florin-Andrei Taran

Published in: Journal of Cancer Research and Clinical Oncology | Issue 11/2017

Login to get access

Abstract

Purpose

The presence of disseminated tumor cells (DTC) in the bone marrow of endometrial carcinoma patients has been demonstrated previously. In contrast to breast cancer, no prognostic significance or association with clinicopathological features was revealed for endometrial carcinoma so far. The aim of this study was to investigate DTC in a large patient cohort with in-depth pathology review data available and to study DTC occurrence in the context of L1CAM and long-term disease specific follow-up.

Methods

Patients treated for endometrial carcinoma at the Tuebingen University Women’s hospital between 2003 and 2013 were identified. Cases with previous expert central pathology review including L1CAM immunohistochemistry and bone marrow aspirates available were selected. The presence of DTC and L1CAM expression was studied immunohistochemically.

Results

In 395 cases with a confirmed diagnosis of endometrial carcinoma, bone marrow aspirates were available. DTC were detected in 17.2%. The presence of DTC was independent from tumor histology, grade, lymphovascular space involvement (LVSI), FIGO stage, myoinvasion, L1CAM immunoreactivity, and nodal metastasis. DTC occurred less frequently in cases with a microcystic elongated and fragmented (MELF) pattern of invasion (2.2 vs. 21.8%, p = 0.0003). Disease progression was distributed equally among patients with and without DTC present.

Conclusions

We were able to confirm previous findings of DTC presence in a large well-characterized cohort of endometrial carcinoma patients. DTC are detectable in almost one-fifth of endometrial carcinoma and occur less frequently with a MELF pattern of invasion. Further studies investigating the role of DTC in endometrial carcinoma are warranted.
Literature
go back to reference Baccelli I et al (2013) Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol 31:539–544. doi:10.1038/nbt.2576 CrossRefPubMed Baccelli I et al (2013) Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol 31:539–544. doi:10.​1038/​nbt.​2576 CrossRefPubMed
go back to reference Fogel M, Harari A, Muller-Holzner E, Zeimet AG, Moldenhauer G, Altevogt P (2014) A standardized staining protocol for L1CAM on formalin-fixed, paraffin-embedded tissues using automated platforms. Int J Biol Mark 29:180–183. doi:10.5301/jbm.5000055 CrossRef Fogel M, Harari A, Muller-Holzner E, Zeimet AG, Moldenhauer G, Altevogt P (2014) A standardized staining protocol for L1CAM on formalin-fixed, paraffin-embedded tissues using automated platforms. Int J Biol Mark 29:180–183. doi:10.​5301/​jbm.​5000055 CrossRef
go back to reference Hertel JD, Huettner PC, Pfeifer JD (2014) Lymphovascular space invasion in microcystic elongated and fragmented (MELF)-pattern well-differentiated endometrioid adenocarcinoma is associated with a higher rate of lymph node metastasis. Int J Gynecol Pathol 33:127–134. doi:10.1097/PGP.0b013e318285657b CrossRefPubMed Hertel JD, Huettner PC, Pfeifer JD (2014) Lymphovascular space invasion in microcystic elongated and fragmented (MELF)-pattern well-differentiated endometrioid adenocarcinoma is associated with a higher rate of lymph node metastasis. Int J Gynecol Pathol 33:127–134. doi:10.​1097/​PGP.​0b013e318285657b​ CrossRefPubMed
go back to reference Joehlin-Price AS et al (2017) The microcystic, elongated, and fragmented (MELF) pattern of invasion: a single institution report of 464 consecutive FIGO grade 1 endometrial endometrioid adenocarcinomas. Am J Surg Pathol 41:49–55. doi:10.1097/PAS.0000000000000754 CrossRefPubMed Joehlin-Price AS et al (2017) The microcystic, elongated, and fragmented (MELF) pattern of invasion: a single institution report of 464 consecutive FIGO grade 1 endometrial endometrioid adenocarcinomas. Am J Surg Pathol 41:49–55. doi:10.​1097/​PAS.​0000000000000754​ CrossRefPubMed
go back to reference Pelletier MP, Trinh VQ, Stephenson P, Mes-Masson AM, Samouelian V, Provencher DM, Rahimi K (2017) Microcystic, elongated, and fragmented pattern invasion is mainly associated with isolated tumor cell pattern metastases in International Federation of Gynecology and Obstetrics grade I endometrioid endometrial cancer. Hum Pathol 62:33–39. doi:10.1016/j.humpath.2016.10.023 CrossRefPubMed Pelletier MP, Trinh VQ, Stephenson P, Mes-Masson AM, Samouelian V, Provencher DM, Rahimi K (2017) Microcystic, elongated, and fragmented pattern invasion is mainly associated with isolated tumor cell pattern metastases in International Federation of Gynecology and Obstetrics grade I endometrioid endometrial cancer. Hum Pathol 62:33–39. doi:10.​1016/​j.​humpath.​2016.​10.​023 CrossRefPubMed
go back to reference Sanci M, Gungorduk K, Gulseren V, Karadeniz T, Kocaer M, Gungorduk O, Ozdemir IA (2017) MELF pattern for predicting lymph node involvement and survival in grade I–II endometrioid-type endometrium cancer. Int J Gynecol Pathol. doi:10.1097/PGP.0000000000000370 PubMed Sanci M, Gungorduk K, Gulseren V, Karadeniz T, Kocaer M, Gungorduk O, Ozdemir IA (2017) MELF pattern for predicting lymph node involvement and survival in grade I–II endometrioid-type endometrium cancer. Int J Gynecol Pathol. doi:10.​1097/​PGP.​0000000000000370​ PubMed
go back to reference Stewart CJ, Brennan BA, Leung YC, Little L (2009) MELF pattern invasion in endometrial carcinoma: association with low grade, myoinvasive endometrioid tumours, focal mucinous differentiation and vascular invasion. Pathology 41:454–459CrossRefPubMed Stewart CJ, Brennan BA, Leung YC, Little L (2009) MELF pattern invasion in endometrial carcinoma: association with low grade, myoinvasive endometrioid tumours, focal mucinous differentiation and vascular invasion. Pathology 41:454–459CrossRefPubMed
Metadata
Title
Disseminated tumor cells are not associated with established risk factors, L1CAM immunoreactivity and outcome in endometrial carcinoma
Authors
Stefan Kommoss
Andreas D. Hartkopf
Bernhard Krämer
Anne-Kathrin Bunz
Friederike Grevenkamp
Felix Kommoss
Jana Pasternak
Sabine M. Arbabi
Markus Wallwiener
Annette Staebler
Sigurd F. Lax
Sara Y. Brucker
Florin-Andrei Taran
Publication date
01-11-2017
Publisher
Springer Berlin Heidelberg
Published in
Journal of Cancer Research and Clinical Oncology / Issue 11/2017
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-017-2474-7

Other articles of this Issue 11/2017

Journal of Cancer Research and Clinical Oncology 11/2017 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.